BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31704735)

  • 1. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers.
    Kim CG; Jang M; Kim Y; Leem G; Kim KH; Lee H; Kim TS; Choi SJ; Kim HD; Han JW; Kwon M; Kim JH; Lee AJ; Nam SK; Bae SJ; Lee SB; Shin SJ; Park SH; Ahn JB; Jung I; Lee KY; Park SH; Kim H; Min BS; Shin EC
    Sci Immunol; 2019 Nov; 4(41):. PubMed ID: 31704735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-driven PD-1
    Maschmeyer P; Heinz GA; Skopnik CM; Lutter L; Mazzoni A; Heinrich F; von Stuckrad SL; Wirth LE; Tran CL; Riedel R; Lehmann K; Sakwa I; Cimaz R; Giudici F; Mall MA; Enghard P; Vastert B; Chang HD; Durek P; Annunziato F; van Wijk F; Radbruch A; Kallinich T; Mashreghi MF
    Eur J Immunol; 2021 Apr; 51(4):915-929. PubMed ID: 33296081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma.
    Prall F; Hühns M
    Histopathology; 2017 Sep; 71(3):366-374. PubMed ID: 28383777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
    Lv J; Jia Y; Li J; Kuai W; Li Y; Guo F; Xu X; Zhao Z; Lv J; Li Z
    Cell Death Dis; 2019 May; 10(6):415. PubMed ID: 31138779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer.
    Tomé M; Pappalardo A; Soulet F; López JJ; Olaizola J; Leger Y; Dubreuil M; Mouchard A; Fessart D; Delom F; Pitard V; Bechade D; Fonck M; Rosado JA; Ghiringhelli F; Déchanet-Merville J; Soubeyran I; Siegfried G; Evrard S; Khatib AM
    Cancer Res; 2019 Oct; 79(19):5008-5021. PubMed ID: 31358531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
    Gong J; Wang C; Lee PP; Chu P; Fakih M
    J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype molding of T cells in colorectal cancer by single-cell analysis.
    Di J; Liu M; Fan Y; Gao P; Wang Z; Jiang B; Su X
    Int J Cancer; 2020 Apr; 146(8):2281-2295. PubMed ID: 31901134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic.
    Phillips SM; Banerjea A; Feakins R; Li SR; Bustin SA; Dorudi S
    Br J Surg; 2004 Apr; 91(4):469-75. PubMed ID: 15048750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.